STAT+: Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million
Written by
STAT News
Published
0
comments
0
min
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.